ARS Pharma Reports Business Highlights and Third Quarter 2026 Financial Results
Globe Newswire•05/11/2026•16:01 ET
0
Key Highlights
- ➤Q3 revenue $37.7 million, up from $32.5 million year over year
- ➤neffy U.S. net product revenue $33.4 million, up from $31.3 million
- ➤Total U.S. neffy market share reached 5%, up from 4% year over year
- ➤SG&A expenses $43.5 million, down 42% from first-half 2026 quarterly average
- ➤ARS-2 interim Phase 2b data expected in first quarter of 2027
Expert Statements
Donn Casale, President and Chief Executive Officer of ARS Pharma
“In August, we committed to three corporate priorities – steady market share gains with neffy, greater financial discipline with a path to cash flow breakeven by year-end 2027, and expansion of our needle-free epinephrine platform beyond anaphylaxis. I’m proud to report that our team has delivered on each”
Donn Casale, President and Chief Executive Officer of ARS Pharma
“Market share grew where our field team engaged; operating expenses were in line with guidance, including a 42% reduction in third-quarter SG&A expenses from the first-half 2026 quarterly average; and ARS-2 is on track for interim Phase 2b data in the first quarter of 2027.”
Donn Casale, President and Chief Executive Officer of ARS Pharma
“These results build the foundation for our future-looking three-pillar growth strategy – capture market share with neffy in our base market; expand the epinephrine market over time; and extend our platform, starting with our chronic spontaneous urticaria. With new leadership in place across our commercial, medical and legal functions, we have the team, the strategy and the discipline to execute. The opportunity in front of us is significant, and we believe we are well positioned to pursue it with focus and urgency.”
Meg Smith, Chief Commercial Officer of ARS Pharma
“neffy is a highly differentiated product in a large market with genuine demand, and I am confident it can become the standard of care in the epinephrine market.”
Meg Smith, Chief Commercial Officer of ARS Pharma
“The data show that when we engage providers directly, neffy wins. In my first two months, we completed a comprehensive assessment of our commercial operations, and we are taking decisive action across multiple fronts, including implementing a shift to account-based targeting, sharper provider-focused messaging, and a strengthened market access strategy. We are moving with urgency, and I expect the progress will continue to be reflected in our results, with steady gains over time.”
Total Q3 revenue of $37.7 million, including $33.4 million in U.S. net product revenue for neffy(®)
neffy U.S. market share reached 5% overall and 9% in field-targeted accounts, supporting the company’s updated targeted provider commercial strategy
Get started
Create a free account to read the full story.